Prevention of sudden cardiac death: The role of the implantable cardioverter-defibrillator

Sunil Sinha, Davendra Mehta, J. Anthony Gomes

Research output: Contribution to journalArticle

Abstract

Sudden cardiac death, usually due to fatal ventricular tachyarrhythmias, results in the loss of 300,000-400,000 lives each year in the United States. Implantable cardioverter-defibrillator therapy has revolutionized both the secondary and, increasingly, the primary prevention of sudden cardiac death. In the last decade, subcutaneous pectoral implantation with transvenous lead placement has lessened perioperative risk considerably, raising the benefit/risk ratio for many candidates. As a consequence, the list of approved indications for implantable cardioverter-defibrillator therapy has expanded rapidly in recent years. Current devices offer tiered therapy utilizing bradycardia pacing, anti-tachycardia pacing, low-energy cardioversion, and high-energy defibrillation. Hybrid therapy, combining device, drugs and radiofrequency catheter ablation as required, has become the standard of care for reducing booth appropriate and inappropriate shocks. As implantation rates continue to rise, so will the number of patients presenting with electrical storm. The dilemma of how our society will cope with the enomous projected costs of implantable cardioverter-defibrillator therapy has yet to be resolved.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalMount Sinai Journal of Medicine
Volume72
Issue number1
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

Implantable Defibrillators
Sudden Cardiac Death
Tachycardia
Therapeutics
Equipment and Supplies
Electric Countershock
Catheter Ablation
Primary Prevention
Standard of Care
Bradycardia
Shock
Odds Ratio
Costs and Cost Analysis
Pharmaceutical Preparations

Keywords

  • Electrical storm
  • Hybrid therapy
  • Implantable cardioverter-defribrillator
  • Inappropriate shocks
  • Sudden cardiac death
  • Tiered therapy
  • Ventricular fibrillation
  • Ventricular tachycardia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prevention of sudden cardiac death : The role of the implantable cardioverter-defibrillator. / Sinha, Sunil; Mehta, Davendra; Gomes, J. Anthony.

In: Mount Sinai Journal of Medicine, Vol. 72, No. 1, 01.2005, p. 1-9.

Research output: Contribution to journalArticle

@article{ea57dcdcbf474335a63a0ab3baa274d4,
title = "Prevention of sudden cardiac death: The role of the implantable cardioverter-defibrillator",
abstract = "Sudden cardiac death, usually due to fatal ventricular tachyarrhythmias, results in the loss of 300,000-400,000 lives each year in the United States. Implantable cardioverter-defibrillator therapy has revolutionized both the secondary and, increasingly, the primary prevention of sudden cardiac death. In the last decade, subcutaneous pectoral implantation with transvenous lead placement has lessened perioperative risk considerably, raising the benefit/risk ratio for many candidates. As a consequence, the list of approved indications for implantable cardioverter-defibrillator therapy has expanded rapidly in recent years. Current devices offer tiered therapy utilizing bradycardia pacing, anti-tachycardia pacing, low-energy cardioversion, and high-energy defibrillation. Hybrid therapy, combining device, drugs and radiofrequency catheter ablation as required, has become the standard of care for reducing booth appropriate and inappropriate shocks. As implantation rates continue to rise, so will the number of patients presenting with electrical storm. The dilemma of how our society will cope with the enomous projected costs of implantable cardioverter-defibrillator therapy has yet to be resolved.",
keywords = "Electrical storm, Hybrid therapy, Implantable cardioverter-defribrillator, Inappropriate shocks, Sudden cardiac death, Tiered therapy, Ventricular fibrillation, Ventricular tachycardia",
author = "Sunil Sinha and Davendra Mehta and Gomes, {J. Anthony}",
year = "2005",
month = "1",
language = "English (US)",
volume = "72",
pages = "1--9",
journal = "Annals of Global Health",
issn = "2214-9996",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Prevention of sudden cardiac death

T2 - The role of the implantable cardioverter-defibrillator

AU - Sinha, Sunil

AU - Mehta, Davendra

AU - Gomes, J. Anthony

PY - 2005/1

Y1 - 2005/1

N2 - Sudden cardiac death, usually due to fatal ventricular tachyarrhythmias, results in the loss of 300,000-400,000 lives each year in the United States. Implantable cardioverter-defibrillator therapy has revolutionized both the secondary and, increasingly, the primary prevention of sudden cardiac death. In the last decade, subcutaneous pectoral implantation with transvenous lead placement has lessened perioperative risk considerably, raising the benefit/risk ratio for many candidates. As a consequence, the list of approved indications for implantable cardioverter-defibrillator therapy has expanded rapidly in recent years. Current devices offer tiered therapy utilizing bradycardia pacing, anti-tachycardia pacing, low-energy cardioversion, and high-energy defibrillation. Hybrid therapy, combining device, drugs and radiofrequency catheter ablation as required, has become the standard of care for reducing booth appropriate and inappropriate shocks. As implantation rates continue to rise, so will the number of patients presenting with electrical storm. The dilemma of how our society will cope with the enomous projected costs of implantable cardioverter-defibrillator therapy has yet to be resolved.

AB - Sudden cardiac death, usually due to fatal ventricular tachyarrhythmias, results in the loss of 300,000-400,000 lives each year in the United States. Implantable cardioverter-defibrillator therapy has revolutionized both the secondary and, increasingly, the primary prevention of sudden cardiac death. In the last decade, subcutaneous pectoral implantation with transvenous lead placement has lessened perioperative risk considerably, raising the benefit/risk ratio for many candidates. As a consequence, the list of approved indications for implantable cardioverter-defibrillator therapy has expanded rapidly in recent years. Current devices offer tiered therapy utilizing bradycardia pacing, anti-tachycardia pacing, low-energy cardioversion, and high-energy defibrillation. Hybrid therapy, combining device, drugs and radiofrequency catheter ablation as required, has become the standard of care for reducing booth appropriate and inappropriate shocks. As implantation rates continue to rise, so will the number of patients presenting with electrical storm. The dilemma of how our society will cope with the enomous projected costs of implantable cardioverter-defibrillator therapy has yet to be resolved.

KW - Electrical storm

KW - Hybrid therapy

KW - Implantable cardioverter-defribrillator

KW - Inappropriate shocks

KW - Sudden cardiac death

KW - Tiered therapy

KW - Ventricular fibrillation

KW - Ventricular tachycardia

UR - http://www.scopus.com/inward/record.url?scp=14044274203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14044274203&partnerID=8YFLogxK

M3 - Article

C2 - 15682255

AN - SCOPUS:14044274203

VL - 72

SP - 1

EP - 9

JO - Annals of Global Health

JF - Annals of Global Health

SN - 2214-9996

IS - 1

ER -